Almost every diabetic patient in Indonesia that requires insulin to control their blood sugar is treated with the newer generation insulin analogue, despite internationally recognized guidance\(^1,\ 2\) that low and middle-income countries (LMICs) should aim to use the less costly human insulin, the first generation of man-made insulin, as a first line treatment.

After examining the costs and clinical benefits of insulin analogue compared with human insulin for Indonesia, our study revealed Indonesia could save 9 million USD annually by switching from insulin analogue to human insulin, which studies have shown does not have substantially better outcomes; and in conjunction negotiating the same prices agreed by neighbouring Thailand.\(^3\)

We recommend clinical practice guidelines are introduced that state human insulin is the first line treatment for type 2 diabetics in Indonesia. The Indonesian Ministry of Health should explore negotiating with pharmaceutical companies for more globally competitive prices.

---

3. This is based 2017 volume data.

* This is based exchange rate on 1 August 2018 (Data from https://www.imf.org), 1 USD = 14,442 IDR
Background to the study and evidence used

With the rising burden of non-communicable diseases in Indonesia will come an increasing need for Insulin. It is predicted that 21 million Indonesians will be living with diabetes by 2030 and 10-15% of these patients will require insulin to control blood glucose and prevent other severe complications.4

BPJS, the Indonesian National Health Insurance System, currently runs an annual budget deficit, so it is vital Indonesia uses resources effectively – especially in its quest to achieve Universal Health Coverage.

We examined studies included in a systematic review by Sabirin and Rahim (2012) on the effectiveness of analogue versus human insulins for type 2 diabetes patients; we then systematically searched and reviewed all studies published from January 2012-April 2017. 14 randomised controlled trials were identified that were suitable to compare clinical outcomes between insulin analogue and human insulin.

We looked at volume data from 2016 for Indonesia5 and from 2017 in Thailand6, and used 2018 prices of insulin under UHC schemes7 to forecast potential budget savings supposing Indonesia could negotiate better prices. Our analysis assumed that administrative form (vials/pens/cartridges) did not change, only whether the insulin was human or analogue.

Treating 11 and 8 patients with insulin analogue can avert one additional case of symptomatic and nocturnal hypoglycaemia respectively. Treating 20 with analogue can lead one additional patient to achieve HbA1C target. Analogue has no advantage in reducing mean HbA1c or severe hypoglycaemia.

High prices of human insulin in Indonesia

Insulin analogue and human insulin are similarly priced in Indonesia. Compared to Thailand, Insulin analogue is 20% cheaper in Indonesia, but human insulin is much more expensive with vials costing four times as much, and pens/cartridges twice as much. Human insulin in Thailand is significantly cheaper than any insulin available in Indonesia.

Budget savings

Indonesian health insurance can save 14% of current spending on insulin if human insulin is used to treat 97% of patients, as it was in Thailand in 2017. It can save 65% of current spending if human insulin is also procured at Thai prices. 65% of current spending on insulin is equivalent to 9,074,885 USD annually.

It is predicted that 21 million Indonesians will be living with diabetes by 2030.

Key findings


5 BPJS Kesehatan, Indonesia

6 National Health Security Office, Thailand

7 E-Katalog, Indonesia: Available from: https://e-katalog.lkpp.go.id/;
Drug and Medical Supply Information Center, Ministry of Public Health, Thailand [Internet], 2018 [cited 5 April 2018]. Available from:
What does this mean for Indonesia?

The high use of insulin analogue in Indonesia is concerning given that it is more expensive and has limited clinical benefits. Its prevalent use also disregards World Health Organization (WHO) and UK guidelines and global trends, particularly amongst LMICs\(^8\). We propose Indonesia use human insulin as first line treatment, and analogue for patients who struggle to control hypoglycaemic events through human insulin or other means.

The Indonesian Ministry of Health should tackle these issues in order to make considerable budget savings and move toward achieving Universal Health Coverage.

---

**POTENTIAL SAVING FROM THE USE OF HUMAN INSULIN**

<table>
<thead>
<tr>
<th>Use in 0.5% of cases (current situation in Indonesia) at Thai price</th>
<th>Use in 97% of cases at current price in Indonesia</th>
<th>Use in 97% of cases at Thai price</th>
</tr>
</thead>
<tbody>
<tr>
<td>60,000 USD SAVED ANNUALLY (0.5% of current spending on insulin)</td>
<td>2 MILLION USD SAVED ANNUALLY (14% of current spending on insulin)</td>
<td>9 MILLION USD SAVED ANNUALLY (65% of current spending on insulin)</td>
</tr>
</tbody>
</table>

---

Policy recommendations

- The Indonesian Ministry of Health should work with professional associations to establish clinical practice guidelines, specifying detailed medical indications to target the use of insulin analogues to patients who struggle to manage blood glucose, or symptomatic and nocturnal hypoglycaemia through use of human insulin or other treatment methods.
- BPJS should only reimburse insulin analogue for those patients who meet the criteria, and should monitor utilization patterns to ensure appropriate prescription occurs.
- The Indonesian Ministry of Health should work with local and international pharmaceutical companies to ensure availability of human insulin and at a lower price. This may require taking legal action if anti-competitive market collusion is confirmed.

Acknowledgement

This Policy Brief is a part of the collaboration between the Indonesian Ministry of Health and Health Intervention and Technology Assessment Program (HITAP) through the international Decision Support Initiative (iDSI). HITAP is funded by the Thailand Research Fund under the senior research scholar on Health Technology Assessment (RTA5980011). HITAP’s international unit has been supported by the international Decision Support Initiative (funded by the Bill & Melinda Gates Foundation and the Department for International Development, UK), and the Rockefeller Foundation to provide technical assistance on health intervention and technology assessment for governments of low- and middle-income countries. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the funding agencies.

We would also like to thank Dr.Ryan Li and Madeleine Stewart, Global Health and Development Group, School of Public Health, Imperial College London, for comments and English editing of this policy brief.

Authors

Juliet Eames, Technical Adviser¹
Waranya Rattanavipapong, Researcher¹
dr. Eva Herlinawaty, Researcher²
Dr. Yot Teerawattananon, Senior Researcher¹

Investigators and Co-Investigators:

- dr. Eva Herlinawaty, Researcher²
- Mazda Novi Mukhisa, Researcher²
- Ida Susanti, Researcher²
- Andi Leni Susyanti, Researcher²
- Mukhissul Faath, Researcher²
- Kittiphong Thiboonboon, Researcher³
- Assoc. Prof. Dr. Thunyarat Anothaisintawee, Researcher¹³
- Juliet Eames, Technical Adviser¹
- Waranya Rattanavipapong, Researcher¹
- Manushi Sharma, Project Associate¹
- Dr. Yot Teerawattananon, Senior Researcher¹

Contact

Juliet Eames: juliet.e@hitap.net

Policy Brief: Health Technology Assessment on Insulin Analogue as Treatment for Type 2 Diabetes in Indonesia

For more information on this study, please go to www.globalhitap.net/projects/idsi-indonesia